Analyst Price Target is $48.78
▲ +22.39% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Qiagen in the last 3 months. The average price target is $48.78, with a high forecast of $52.50 and a low forecast of $43.75. The average price target represents a 22.39% upside from the last price of $39.85.
Current Consensus is
Hold
The current consensus among 9 polled investment analysts is to hold stock in Qiagen. This rating changed within the last month from a Moderate Buy consensus rating.
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
Read More